Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, wh
Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. EDT during EULAR 2020. The event will follow Thurs
Blair William & Co. IL Sells 38,930 Shares of Nektar Therapeutics (NASDAQ:NKTR)
09:27am, Wednesday, 27'th May 2020
Blair William & Co. IL reduced its position in Nektar Therapeutics (NASDAQ:NKTR) by 13.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchang
7 Stocks Maverick Capital Continues to Buy
03:11pm, Tuesday, 26'th May 2020
Adobe and Avantor make the list Continue reading...
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab,
Patent Filings Roundup: The Return of the Founder, Retailers Target Wireless LLC, European NPE Revives 2G/3G Patent Wars
04:15pm, Wednesday, 20'th May 2020
There were only 16 new patent filings at the Patent Trial and Appeal Board (PTAB)—all inter partes reviews (IPRs)—this week, with a whopping 70 new district court complaints filed.
Wolf's Corona Discounts: Bristol-Myers Squibb (NYSE:BMY)
02:33pm, Tuesday, 19'th May 2020
It's finally time to write about my favorite pharma stock in the corona-discount model. Bristol-Myers Squibb has gone from being a rather insignificant holding
Oppenheimer Maintains Perform on Nektar Therapeutics, Raises Price Target to $25
12:23pm, Monday, 18'th May 2020Is There An Opportunity With Nektar Therapeutics's (NASDAQ:NKTR) 46% Undervaluation?
12:05pm, Monday, 18'th May 2020
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Nektar Therapeutics...
Oppenheimer Sticks to Their Hold Rating for Nektar Therapeutics
11:13pm, Sunday, 17'th May 2020
Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22
8-K: BioXcel Therapeutics, Inc.
03:39am, Wednesday, 13'th May 2020
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2020 Results - Earnings Call Transcript
07:02pm, Tuesday, 12'th May 2020
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2020 Results Conference Call May 12, 2020 08:30 AM ET Company Participants Vimal Mehta - Founder and CEO Richard Ste
